Ad

ANVS

🔒

Subscribe for full access

Unlock Industry-grade Shariah Compliance for US, UK, Canada, Germany, GCC, Europe and India. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.

We provide unparalleled value and service.

Get started from just $1/month

Ad

Recommendation Rating

1.5

1

2

3

4

5

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Analysts’ Price Targets

Mean 31.5

Low: 26

High: 37

Total Analysts: 2

Company Profile

Annovis Bio, Inc. is a clinical-stage drug platform company. The Company is engaged in developing treatments for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s disease in Down syndrome (AD-DS). The Company’s lead compound, Buntanetap, is an orally administered drug being developed for chronic indications such as AD, PD and AD-DS. The Company’s ANVS405 compound is being developed for acute indications, focused on protecting the brain after Traumatic brain injury (TBI) and/or stroke. Its ANVS405 is the same compound as Buntanetap, but it is given intravenously in cases of acute head and brain trauma. The Company is also developing its compound, ANVS301 to increase cognitive capability in later stages of AD and dementia.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses